November 11, 2015
4D pharma gets OK for clinical trial of Thetanix
4D pharma has obtained regulatory and ethical approval for a phase 1 clinical trial in respect of Thetanix.
pharmaceutical daily
Pharmaceuticals, Biotechnology and Life Sciences
November 11, 2015
Biofrontera’s business not affected by ongoing approval processes
Biofrontera has announced that there have been no new operational developments or matters which have arisen in relation to the ongoing approval processes or other operational aspects of the Company.
November 11, 2015
Plavix does not affect overall risk of death in patients with heart disease.
Long-term use of the blood-thinning drug Plavix (clopidogrel) does not increase or decrease overall risk of death in patients with, or at risk for, heart disease.
November 11, 2015
Diplomat to dispense melanoma drug “Cotellic” in combination with “Zelboraf”
Diplomat Pharmacy, NYSE-listed pharmaceutical company, will dispense Cotellic in combination with the BRAF inhibitor Zelboraf to treat patients with advanced melanoma that cannot be removed by surgery, or that has spread from the primary site.
November 11, 2015
Well-matched influenza vaccine prevents P&I hospitalizations and mortality in NH residents
Well-matched influenza vaccine prevents P&I hospitalizations and mortality in NH residents.
November 11, 2015
Allergan submits Prior Approval Supplement for RESTASIS
Allergan has submitted a Prior Approval Supplement (PAS) for RESTASIS (Cyclosporine Ophthalmic Emulsion) 0.05%, seeking approval of a Multi-Dose Preservative-Free (MDPF) presentation.
November 10, 2015
Inaffit pulls back Natureal light and dark green capsules
Inaffit is voluntarily recalling all lots of Natureal light green and dark green capsules to the consumer level after FDA laboratory testing found Natureal to contain sibutramine.
November 10, 2015
Zenobia recalls Ground Flax Seed Meal due to salmonella
Zenobia Company LLC. of Yonkers, NY is recalling Ground Flax Seed Meal, because they have the potential to be contaminated with Salmonella.
November 9, 2015
Lilly’s ixekizumab shows improvements in signs and symptoms of their disease when compared to placebo
Eli Lilly and Company has announced that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant improvements…
November 9, 2015
Sanofi’s and Regeneron’s study shows improvements in signs and symptoms of rheumatoid arthritis
Sanofi and Regeneron Inc. have announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against…